Clinical Trial Update: Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI. [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial comparing cangrelor, tirofiban, and prasugrel in patients with STEMI referred for primary PCI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• St-elevation Myocardial Infarction

Drugs mentioned

• Cangrelor (cangrelor)
• PRASUGREL (prasugrel)
• tirofiban (tirofiban)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Coronary Artery Disease, STEMI - ST Elevation Myocardial Infarction | Phase 4 | Status: COMPLETED